

W1 J0829  
V.83 NO.7 1994  
C.01-----SEO: J34360000  
TI: JOURNAL OF PHARMACEUTICAL  
SCIENCES 07/25/94

**July 1994**

Volume 83

Number 7

JOURNAL OF  
**Pharmaceutical  
Sciences**



PROPERTY OF THE  
NATIONAL  
LIBRARY OF  
MEDICINE




A publication of the  
**American  
Pharmaceutical  
Association**  
and the  
**American  
Chemical  
Society**



# Chronicles of Drug Discovery

Volume 3



EDITED BY  
Daniel Lednicer



ACS Professional Reference Book

**NEW TITLE**

This fascinating new book, **Chronicles of Drug Discovery, Volume 3**, offers a unique insight into the drug discovery process through informal histories presented by the drugs' inventors. It provides a compilation of accounts describing the events leading from the initial discovery to successful introduction on the market of fourteen important new drugs, including RU 486 (mifepristone) and taxol. Many chapters outline in detail the chemical/biological rationale which led to the discovery. The volume also includes drugs with a wide selection of therapeutic indications and presents a broad range of development strategies.

### Contents:

- Mifepristone
- Loratadine
- Enalapril and Lisinopril
- Esmolol
- Aztreonam
- Camptothecin and Taxol
- Ranitidine
- Misoprostol
- Flecainide
- Diltiazem
- Ganciclovir
- Etoposide
- Amsacrine

Daniel Lednicer, National Cancer Institute, Editor  
ACS Professional Reference Book  
350 pages (1993)  
Clothbound: ISBN 0-8412-2523-0—\$84.95  
Paperbound: ISBN 0-8412-2733-0—\$34.95

### Order from:

American Chemical Society  
Distribution Office, Dept. 74  
1155 Sixteenth Street, NW  
Washington, DC 20036

### Or CALL TOLL FREE

**1-800-227-5558** (in Washington,  
DC, 202-872-4363) and use your  
credit card! FAX: 202-872-6067

**ACS PUBLICATIONS**  
Essential Resources for the Chemical Sciences

# JOURNAL OF Pharmaceutical Sciences

*Journal of Pharmaceutical Sciences* (ISSN 0022-3549) is copublished monthly by the American Chemical Society, 1155 16th St., N.W., Washington, DC 20036, and the American Pharmaceutical Association, 2215 Constitution Ave., N.W., Washington, DC 20037. Second-class postage paid at Washington, DC, and additional mailing offices. POSTMASTER: Send address changes to *Journal of Pharmaceutical Sciences*, Member & Subscriber Services, P.O. Box 3337, Columbus, OH 43210 (614) 447-3776; (800) 333-9511.

Canadian GST Reg. No. R127571347.  
Printed in the USA.

### MANAGEMENT BOARD

American Chemical Society

Robert H. Marks

Charles R. Bertsch

American Pharmaceutical Association

James P. Caro

Joan S. Zaro

### Journals Department

American Chemical Society

2540 Olentangy River Road

P.O. Box 3330

Columbus, OH 43210

(614) 447-3600, Ext. 3171

TELEX 6842086

FAX (614) 447-3745

Manager: Mary E. Scanlan

Journals Editing Managers: Kathleen E. Duffy,

Anne C. O'Melia, and Joseph E. Yurvati

Assistant Editor: Mary Jo Lesheski

### Office of

*Journal of Pharmaceutical Sciences*

American Pharmaceutical Association

2215 Constitution Ave., N.W.

Washington, DC 20037

(202) 628-4410

FAX (202) 783-2351

Senior Director, Programming and

Publications: James P. Caro

Administrative Assistant: Susan Ysais

Advertising Office: Centcom, Ltd.,  
1599 Post Road East, P.O. Box 231,  
Westport, CT 06881. Phone: (203) 256-8211.  
FAX: (203) 256-8175.

© Copyright 1994 by the American Chemical Society and the American Pharmaceutical Association. **Copyright permission:** An individual may make a single reprographic copy of an article in this publication for personal use. Reprographic copying beyond that permitted by Section 107 or 108 of the U.S. Copyright Law is allowed, provided that the appropriate per-copy fee is paid through the Copyright Clearance Center, Inc., 222 Rosewood Dr., Danvers, MA 01923. Salem, MA 01970. Reprint permission: For material published prior to 1994, write to Susan Ysais at APhA; for material published after January 1, 1994, write to the Copyright Administrator, Publications Division, at the ACS Washington address. The paper used in this publication meets the minimum requirements of American National Standard for Information Sciences—Permanence of Paper for Printed Library Materials, ANSI Z39.48-1984.

This material was copied  
at the NLM and may be  
Subject US Copyright Laws

### Editorial Information

**Instructions for authors** appears in the January issue. Please conform to these instructions when submitting manuscripts.

**Manuscripts for publication** should be submitted to the Editor, William I. Higuchi, Ph.D., Department of Pharmaceutics and Pharmaceutical Chemistry, 301 Skaggs Hall, University of Utah, Salt Lake City, UT 84112.

Correspondence regarding **accepted papers and proofs** should be directed to the Journals Department, American Chemical Society, at the address given.

**Bulk reprints** of individual articles are available. For information contact Susan Ysais at APhA. Phone: (202)429-7526.

The American Chemical Society, the American Pharmaceutical Association and their Editors assume no responsibility for the statements and opinions advanced by contributors.

Registered names and trademarks, etc., used in this publication, even without specific indication thereof, are not to be considered unprotected by law.

### Subscription and Business Information

**1994 subscription prices**, including postage. Subscriptions are available only on a calendar year basis. (For membership information, contact Office of Member Services at the ACS Washington address or APhA, 2215 Constitution Ave, N.W., Washington, DC 20037.)

	U.S.	Canada and Mexico	Europe*	All Other Countries*
Members	\$ 30	\$ 44	\$ 62	\$ 70
Nonmembers, individual	\$ 85	\$ 99	\$117	\$125
Nonmembers, institutional	\$278	\$292	\$310	\$318

\* Air service included.

APhA member subscriptions should be sent to APhA, 2215 Constitution Ave., N.W., Washington, DC 20037. All other new and renewal subscriptions should be sent with payment to American Chemical Society, Department L-0011, Columbus, OH 43268-0011. Rates quoted do not apply to nonmember subscribers in Japan, who must enter subscription orders with Maruzen Company Ltd., 3-10 Nihonbashi 2-chome, Chuo-ku, Tokyo 103, Japan. Phone: (03) 272-7211.

**Printed edition single issue prices:** Current year, \$35.00. Foreign postage additional. Mail orders should be sent to Microforms & Back Issues Office at the ACS Washington address. For information concerning back issues and volumes prior to Vol. 83 contact the APhA in Washington, DC.

Microfilm, microfiche, and single issues on paper are available from University Microfilms International, 300 N. Zeeb Road, Ann Arbor, MI 48106 [(303) 761-4700].

**Changes of address** must include both old and new addresses with ZIP code and a recent mailing label. Send all address changes to Member & Subscriber Services, American Chemical Society, P.O. Box 3337, Columbus, OH 43210 [(614) 447-3776; (800) 333-9511]. Please allow 6 weeks for change to become effective.

**Claims for missing numbers** will not be allowed if loss was due to failure of notice of change of address to be received in the time specified; if claim is dated (a) North American: more than 90 days beyond issue date, (b) all other foreign: more than 180 days beyond issue date. Claims are handled by Member & Subscriber Services. Claims for Vols. 1-82 should be addressed to APhA.

Mylan v. Qualicaps, IPR2017-00203  
QUALICAPS EX. 2013 - 2/13



**Editor****William I. Higuchi***University of Utah, Department of Pharmaceutics and  
Pharmaceutical Chemistry  
Salt Lake City, UT 84112-1102***Associate Editors****David J. W. Grant***University of Minnesota, Minneapolis, MN***Ho-Leung Fung***State University of New York at Buffalo, Buffalo, NY***Bradley D. Anderson***University of Utah, Salt Lake City, UT***C. Russell Middaugh***Merck and Company, West Point, PA*

# JOURNAL OF Pharmaceutical Sciences



A publication of the  
**American  
Pharmaceutical  
Association**  
and the  
**American  
Chemical  
Society**

**Editorial Advisory Board****Gordon L. Amidon**  
*The University of Michigan  
Ann Arbor, MI***Gregory E. Amidon**  
*The Upjohn Company  
Kalamazoo, MI***James E. Axelson**  
*The University of British  
Columbia  
Vancouver, Canada***Meir Bialer**  
*The Hebrew University  
of Jerusalem  
Jerusalem, Israel***Ronald T. Borchardt**  
*University of Kansas  
Lawrence, KS***David W. A. Bourne**  
*University of Oklahoma  
Oklahoma City, OK***Robert L. Bronaugh**  
*Food & Drug Administration  
Washington, DC***Stephen R. Byrn**  
*Purdue University  
West Lafayette, IN***John F. Carpenter**  
*University of Colorado  
Health Sciences Center  
Denver, CO***Jens T. Carstensen**  
*University of Wisconsin  
Madison, WI***Win Loung Chiou**  
*University of Illinois  
Chicago, IL***James C. Cloyd**  
*University of Minnesota  
Minneapolis, MN***Jeffrey L. Cleland**  
*Genentech, Inc.  
South San Francisco, CA***Kenneth A. Connors**  
*University of Wisconsin  
Madison, WI***Michael G. Cordingley**  
*Bio-Maga/Boehringer Ingelheim  
Quebec, Canada***Daan J. A. Crommelin**  
*University of Utrecht  
Utrecht, The Netherlands***William J. Curatolo**  
*Pfizer Central Research  
Groton, CT***David J. Cutler**  
*University of Sydney  
Sydney, Australia***William E. Evans**  
*St. Jude Children's Research  
Hospital  
Memphis, TN***David Fitzgerald**  
*National Cancer Institute  
Bethesda, MD***William O. Foye**  
*Massachusetts College of  
Pharmacy  
Boston, MA***Jeffrey L. Fox**  
*University of Utah  
Salt Lake City, UT***Emilio Gelpi**  
*CID-CSIC  
Barcelona, Spain***Detlef Groger**  
*Akademie der Wissenschaften  
Halle, Germany***Iris H. Hall**  
*University of North Carolina  
Chapel Hill, NC***Manabu Hanano**  
*University of Tokyo  
Tokyo, Japan***James N. Herron**  
*University of Utah  
Salt Lake City, UT***William J. Jusko**  
*SUNY Buffalo  
Amherst, NY***Stanley A. Kaplan**  
*A.L. Labs, Inc.  
Baltimore, MD***Gerald B. Kasting**  
*Procter & Gamble Company  
Cincinnati, OH***Kristine Knutson**  
*University of Utah  
Salt Lake City, UT***William J. Lambert**  
*Pfizer Central Research  
Groton, CT***Robert S. Langer**  
*Massachusetts Institute of  
Technology  
Cambridge, MA***Abraham M. Lenhoff**  
*University of Delaware  
Newark, DE***Andrew T. McPhail**  
*Duke University  
Durham, NC***Karnal K. Midha**  
*University of Saskatchewan  
Saskatchewan, Canada***Tsuneji Nagai**  
*Hoshi University  
Tokyo, Japan***Michael S. Roberts**  
*University of Queensland  
Brisbane, Australia***Naír Rodríguez-Hornedo**  
*The University of Michigan  
Ann Arbor, MI***Malcom Rowland**  
*University of Manchester  
Manchester, England***Gautam Sanyal**  
*Merck and Company  
West Point, PA***Jiaxiang Shen**  
*State Pharmaceutical  
Administration of China  
Beijing, China***Miklós Simonyi**  
*Hungarian Academy of Sciences  
Budapest, Hungary***Valentino J. Stella**  
*University of Kansas  
Lawrence, KS***Raj G. Suryanarayanan**  
*University of Minnesota  
Minneapolis, MN***Felix Theeuwes**  
*Alza Corporation  
Palo Alto, CA***John A. Thomson**  
*Vertex Pharmaceuticals, Inc.  
Cambridge, MA***Daniel L. Weiner**  
*Quintiles, Inc.  
Research Triangle Park, NC***Dominic J. Wells**  
*The Royal Veterinary College  
London, United Kingdom***Peter York**  
*University of Bradford  
Bradford, United Kingdom***George Zografis**  
*University of Wisconsin  
Madison, WI*



A publication of the  
**American  
Pharmaceutical  
Association**  
and the  
**American  
Chemical  
Society**



# JOURNAL OF Pharmaceutical Sciences

**July 1994**

Volume 83, Number 7  
JPMSAE 83(7) 915-1068  
ISSN 0022-3549

## REVIEW ARTICLE

- Cross-Linking of Gelatin Capsules and Its Relevance to Their in Vitro-in Vivo Performance**  
*George A. Digenis, Thomas B. Gold, and Vinod P. Shah* ..... 915

## RESEARCH ARTICLES

- Interaction of Anionic Compounds with Gelatin. I: Binding Studies**  
*Jaya Gautam and Hans Schott* ..... 922
- Product Inhibition and Dose-Dependent Bioavailability of Propranolol in the Isolated Perfused Rat Liver Preparation**  
*Hany Ghabrial, Romina Nand, Cheryl K. Stead, Richard A. Smallwood, and Denis J. Morgan* ..... 931
- Characterization of Wet Granulation Process Parameters Using Response Surface Methodology. 1. Top-Spray Fluidized Bed**  
*Douglas M. Lipps and Adel M. Sakr* ..... 937
- Estimation and Correlation of Drug Water Solubility with Pharmacological Parameters Required for Biological Activity**  
*Maurice M. Morelock, Louisa L. Choi, Gerald L. Bell, and James L. Wright* ..... 948
- Synthesis of *N*-Heteryl- $\beta$ -[(2-alkoxyethyl)oxy]/ $\beta$ -[[2-(*N,N*-dialkylamino)ethyl]oxy]acetamides as Possible  $H_1$ -Antihistaminics**  
*A. Raghu Ram Rao and V. Malla Reddy* ..... 953
- Effect of Cogrounding Time on the Release of Pentoxifylline from Waxy Matrix Tablets**  
*Makoto Otsuka and Yoshihisa Matsuda* ..... 956
- Interactions of Cimetidine and Ranitidine with Aluminum-Containing Antacids and a Clay-Containing Gastric-Protective Drug in an "Artificial Stomach-Duodenum" Model**  
*J. Vatier, A Harman, N. Castela, M. T. Droy-Lefaix, and R. Farinotti* ..... 962
- Stabilization of Topotecan in Low pH Liposomes Composed of Distearoylphosphatidylcholine**  
*Thomas G. Burke and Xiang Gao* ..... 967
- Pharmacodynamic Modeling of Bacterial Kinetics:  $\beta$ -Lactam Antibiotics against *Escherichia coli***  
*Ronald C. Li, David E. Nix, and Jerome J. Schentag* ..... 970
- Use of Everted Intestinal Rings for *in Vitro* Examination of Oral Absorption Potential**  
*Paula S. Leppert and Joseph A. Fix* ..... 976
- In the Search for New Anticancer Drugs. 26. A Comparison of Anticancer Activities of Several TEPA, Thio-TEPA, Seleno-TEPA, and Azetidone Analogs, Including Congeners Containing an Aminoxyl Moiety**  
*George Sosnovsky, Jan Lukszo, Maria Konieczny, Klaus Purgstaller, and Frank Laib* ..... 982

Contents continued on IV

Journal of Pharmaceutical Sciences / III  
Vol. 83, No. 7, July 1994

Mylan v. Qualicaps, IPR2017-00203  
QUALICAPS EX. 2013 - 4/13



<b>In the Search for New Anticancer Drugs. 27. Synthesis and Comparison of Anticancer Activity in Vivo of Amino Acids, Carbohydrates, and Carbohydrate–Amino Acid Conjugates Containing the [N'-(2-Chloroethyl)-N'-nitrosoamino]carbonyl Group</b> <i>George Sosnovsky and C. Thomas Gnewuch</i> .....	989
<b>In the Search for New Anticancer Drugs. 28. Synthesis and Evaluation of Highly Active Aminoxyl Labeled Amino Acid Derivatives Containing the [N'-(2-Chloroethyl)-N'-nitrosoamino]carbonyl Group</b> <i>George Sosnovsky, Mustafa Baysal, and Ercin Erciyas</i> .....	999
<b>Decreased Toxicity of Liposomal Amphotericin B Due to Association of Amphotericin B with High-Density Lipoproteins: Role of Lipid Transfer Protein</b> <i>Kishor M. Wasan, Richard E. Morton, Michael G. Rosenblum, and Gabriel Lopez-Berestein</i> .....	1006
<b>Ondansetron Absorption in Adults: Effect of Dosage Form, Food, and Antacids</b> <i>Haig P. Bozigan, J. Frederick Pritchard, Ann E. Gooding, and Gary E. Pakes</i> .....	1011
<b>Evaluation of Ultrafiltration for the Free-Fraction Determination of Single Photon Emission Computed Tomography (SPECT) Radiotracers: <math>\beta</math>-CIT, IBF, and Iomazenil</b> <i>Mitchell S. Gandelman, Ronald M. Baldwin, Sami S. Zoghbi, Yolanda Zea-Ponce, and Robert B. Innis</i> ....	1014
<b>Diabetes-Induced Reduction in the Hepatic Accumulation of 70-kDa Dextran: Role of Hyperglycemia and Hypoinsulinemia</b> <i>Reza Mehvar and James Reynolds</i> .....	1020
<b>Quantitative Analyses of the Structure–Hydrophobicity Relationship for N-Acetyl Di- and Tripeptide Amides</b> <i>Miki Akamatsu, Tadashi Katayama, Daisuke Kishimoto, Youichi Kurokawa, Hiroyuki Shibata, Tamio Ueno, and Toshio Fujita</i> .....	1026
<b>New Approaches for the Preparation of Hydrophobic Heparin Derivatives</b> <i>Jian Liu, Azra Pervin, Cindy M. Gallo, Umesh R. Desai, Cornelius L. Van Gorp, and Robert J. Linhardt</i>	1034
<b>Metabolites of Chloroquine: Some Observations on Desethylchloroquine and N-Acetyldesethylchloroquine</b> <i>Aslam M. Ansari and J. Cymerman Craig</i> .....	1040
<b>Liposomal Entrapment of Suramin</b> <i>Hung-Chih Chang and Douglas R. Flanagan</i> .....	1043
<b>Prediction and Experimental Determination of Solute Output from a Collison Nebulizer</b> <i>Anna Y. Ip and Ralph W. Niven</i> .....	1047
<b>Theoretical Perspectives on Anthelmintic Drug Discovery: Interplay of Transport Kinetics, Physicochemical Properties, and in Vitro Activity of Anthelmintic Drugs</b> <i>Norman F. H. Ho, Sandra M. Sims, Thomas J. Vidmar, Jeff S. Day, Craig L. Barsuhn, Eileen M. Thomas, Timothy G. Geary, and David P. Thompson</i> .....	1052

#### COMMUNICATIONS

<b>Nonlinear Disposition of Hydroxyurea</b> <i>William G. Tracewell, William P. Vaughan, and Peter R. Gwilt</i> .....	1060
<b>A “Full-Space” Method for Predicting in Vivo Transdermal Plasma Drug Profiles Reflecting Both Cutaneous and Systemic Variability</b> <i>Patrick L. Williams and Jim E. Riviere</i> .....	1062

#### OPEN FORUM

<b>Comments on “Solvatochromic Linear Solvation Energy Relationship in Describing Drug Solubilities”</b> <i>Daniel C. Leggett</i> .....	1065
<b>Comments Concerning “Pharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etabonate in Rats and Dogs”</b> <i>Kenneth B. Sloan and John H. Perrin</i> .....	1066
<b>Response to the Commentary on “Pharmacokinetic Characterization and Tissue Distribution of the New Glucocorticoid Soft Drug Loteprednol Etabonate in Rats and Dogs”</b> <i>Guenther Hochhaus, Pascal Druzgala, John F. Howes, Nicholas Bodor, and Hartmut Derendorf</i> .....	1067



The American Chemical Society and  
The American Pharmaceutical Association  
acknowledge

**Parke-Davis Pharmaceutical Research**  
A Division of the Warner-Lambert Company

**SmithKline Beecham Pharmaceuticals**  
**Research and Development**

for support of the  
*Journal of Pharmaceutical Sciences*







A publication of the  
**American  
Pharmaceutical  
Association**  
and the  
**American  
Chemical  
Society**



# JOURNAL OF Pharmaceutical Sciences

July 1994  
Volume 83, Number 7

## REVIEW ARTICLE

### Cross-Linking of Gelatin Capsules and Its Relevance to Their in Vitro–in Vivo Performance

GEORGE A. DIGENIS<sup>\*x</sup>, THOMAS B. GOLD<sup>\*</sup>, AND VINOD P. SHAH<sup>‡</sup>

Received October 14, 1993, from the <sup>\*</sup>*Division of Medicinal Chemistry and Pharmaceutics, College of Pharmacy, University of Kentucky, Lexington, KY 40536*, and <sup>‡</sup>*Office of Generic Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20855*. Accepted for publication February 23, 1994<sup>®</sup>.

**Abstract** □ The present review deals with the chemistry of gelatin cross-linking under conditions that are relevant to pharmaceutical situations. Mechanistic rationalizations are offered to explain gelatin cross-linking under "stress" conditions. These include elevated temperature and high humidity conditions. In addition, the chemical interactions between gelatin and aldehydes, such as formaldehyde and other formulation excipients, are discussed. The literature on the in vitro and in vivo dissolution and bioavailability of a drug from stressed gelatin capsules and gelatin-coated tablets is reviewed. Cross-linking phenomena, occurring in stressed hard gelatin capsules and gelatin-coated tablets, could cause considerable changes in the in vitro dissolution profiles of drugs. However, in a few cases, the bioavailability of the drug from the stressed capsules is not significantly altered when compared to that obtained from freshly packed capsules. It is concluded that, as with other drug-delivery systems, careful attention should be paid to the purity and chemical reactivity of all excipients that are to be encapsulated in a gelatin shell. It is suggested that in vitro dissolution tests of hard gelatin-containing dosage forms be conducted in two stages, one in a dissolution medium without enzymes and secondly in dissolution media containing enzymes (pepsin at pH 1.2 or pancreatin at pH 7.2, representing gastric and intestinal media, respectively) prior to in vivo evaluation. Such in vitro tests may constitute a better indication of the in vivo behavior of gelatin-encapsulated formulations. Furthermore, testing for contamination with formaldehyde as well as low molecular weight aldehydes should be a standard part of excipient evaluation procedures.

#### Introduction

Gelatin is a mixture of water-soluble proteins derived primarily from collagen. It is obtained by boiling skin, tendons, ligaments, bones, and other similar products in water. Gelatin is extensively used in solid dosage forms: hard and soft gelatin capsules and


gelatin-coated tablets. It is a favorable material for use as the outer layer of drug formulations because of its glossy appearance, ability to hold dye color, neutral taste, and processing convenience. Gelatin has also been used as a stabilizer, thickener, and texturizer in foodstuffs.

Due to the apparent dissolution problems in in vitro testing of hard and soft capsules, questions have been raised about the potential of cross-linking effects in gelatin.<sup>1</sup> The current literature tends to indicate that these effects primarily impact the in vitro testing methodology rather than the in vivo bioavailability of drugs formulated in hard gelatin capsules. Nevertheless, this chemical reactivity of gelatin must be taken into account when designing the final drug formulation.

In general, the amino acid content of gelatin is glycine, 25.5%; proline, 18%; hydroxyproline, 14.1%; glutamic acid, 11.4%; alanine, 8.5%; arginine, 8.5%; aspartic acid, 6.6%; lysine, 4.1%; leucine, 3.2%; valine, 2.5%; phenylalanine, 2.2%; threonine, 1.9%; isoleucine, 1.4%; methionine, 1.0%; histidine, 0.8%; tyrosine, 0.5%; serine, 0.4%; and cystine and cysteine, 0.1%.<sup>2</sup> Gelatin may be produced by lime hydrolysis of bones and animal skins (type B, isoelectric point = 4.7–5.3) or by acid hydrolysis of animal skins (type A, isoelectric point = 6.0–8.0).<sup>1</sup> Hard gelatin capsules are usually prepared from a mixture of type A and B gelatins.

The reactivity of the gelatin molecule appears to arise from the trifunctional amino acids it contains, specifically, lysine. In type B gelatin, the lysine-derived  $\epsilon$ -amino function content was found to be 33.0 mol/gelatin molecule of 1000 amino acid residues.<sup>3</sup> Carboxyl groups are far more plentiful than amino groups in gelatin but appear to be less reactive in reactions that involve cross-linking.<sup>1</sup> The amino groups arising from histidine residues are generally thought not to play as important a role in gelatin cross-linking as the  $\epsilon$ -amino groups of lysine.<sup>1</sup> The highly basic guanidino group of arginine is protonated at neutral pH and consequently is thought to be unreactive unless a very high pH is employed.<sup>1</sup> More recently, however, the participation

\* Abstract published in *Advance ACS Abstracts*, April 15, 1994.



**Scheme 1**

of arginine in the hardening of gelatin in the presence of formaldehyde has been shown to be eminent.<sup>4-6</sup>

### Chemistry of Gelatin Cross-Linking


The cross-linking of the gelatin molecule is a well-known phenomenon that may occur by one or several chemical reactions.<sup>7</sup> One possible reaction may involve the formation of desmosine-type cross-linking, known to occur in elastin fiber.<sup>8</sup> Lysine residues which are proximal to each other are oxidatively deaminated to yield terminal aldehyde groups. One of the aldehyde groups could then be attacked by a free  $\epsilon$ -amino group of a neighboring lysine to yield an imine which subsequently undergoes a series of aldol-type condensation reactions to produce a cross-linked product containing pyridinium ring(s),<sup>8</sup> (Scheme 1). Another possible gelatin cross-linking event involves the reaction of a lysyl  $\epsilon$ -amino group with an aldehyde (Scheme 2). (Trace quantities of formaldehyde may be present in corn starch,<sup>9-12</sup> which is an excipient in many drug formulations.) The initial product, a (hydroxymethyl)amino group (Scheme 2), eliminates water to give a cationic imine. The imine can react with another (hydroxymethyl)amino lysine residue to yield a dimethylene ether.<sup>1</sup> This ether may then rearrange to form a methylene link between two  $\epsilon$ -amino groups of lysine.

A third example of gelatin cross-linking is the formation of an imine arising from the reaction of the  $\epsilon$ -amino group of lysine and an aldehyde, with subsequent formation of an aminal, the amine form of an acetal (Scheme 3). Step 1 of Scheme 3 involves the formation of a carbinolamine, which is rate limiting in acid pH, while step 3 involves the formation of the imine with concurrent water loss.<sup>13,14</sup> Step 2 is rate limiting in base.<sup>13,14</sup>


The final step (step 4) requires the attack of a free amine on the cationic imine to give the aminal (Scheme 3). The optimal pH of formation of the aminal would inevitably be close to 7 because each step (step 1 or 2) becomes rate limiting on either side of neutral pH. Aminal formation, like that of an acetal, is reversible at low pH. The acidic milieu combined with the presence of enzymes in the stomach explains why cross-linking in gelatin capsules may exert little influence on the in vivo dissolution rate of a drug.

Glucose or other aldose sugars are often included in drug formulations and may provide yet another possibility for gelatin cross-linking. The aldehyde functional group of these saccharides may react with a free  $\epsilon$ -amino group to give an imine intermediate, which, through an Amadori rearrangement,<sup>15</sup> produces a ketose sugar (Scheme 4). The formed aminoglycoside (ketose sugar) is then free to react with another amine through its carbonyl functionality to form the cross-linked gelatin.<sup>9,15</sup>





**Scheme 2**



**Scheme 3**

## Types of Gelatin Cross-Linking


In general, cross-linking within the gelatin polypeptide may occur in one of two ways. Bridging may take place within the same polypeptide strand (intrastrand, intramolecular cross-linking), or amino acid residues from two neighboring peptide strands may form a bridge (interstrand, intermolecular cross-linking) (Figure 1).

Model reactions of the hardening of gelatin with  $^{13}\text{C}$ -labeled formaldehyde have recently been monitored by using  $^{13}\text{C}$  NMR spectroscopy in solution and solid state.<sup>5</sup> It was found that when a 12% gelatin solution is treated with 0.5%  $^{13}\text{C}$ -labeled formaldehyde, the latter first formed methylols (carbinolamines) of lysine residues and subsequently of arginine residues. After longer incubation periods with formaldehyde (72 h) lysine-arginine amination (cross-links) are formed (Figure 1). During the drying process of hardened gelatin, in addition to the lysine-


arginine cross-link, an arginine-arginine cross-link appears to form (Figure 1). Humidity strongly influences the rate of this cross-linking process.<sup>5</sup>

## Agents Which Catalyze Gelatin Cross-Linking

Gelatin capsules undergo conformational change and cross-linking when stored under high-humidity conditions, as demonstrated by gemfibrozil, hydrochlorothiazide, and diphenhydramine hydrochloride capsules.<sup>16</sup> The cross-linking process causes formation of a swollen, rubbery, water-insoluble membrane (pellicle) during dissolution testing.<sup>17-19</sup> This water-insoluble gelatin film acts as a barrier, restricting drug release. The mechanism through which humidity probably acts is by indirect catalysis of imine formation, which is the first intermediate in all the cross-linking reactions listed in the previous



**Scheme 4**




**Figure 1**

section. For example, corn starch, a drug excipient, may contain traces of the stabilizer hexamethylenetetramine,<sup>9-12</sup> which decomposes under humid conditions to form ammonia and formaldehyde (Scheme 5).<sup>20</sup> The latter may react with lysine residues present in gelatin to form imines, which subsequently



can undergo any of the possible cross-linking reactions described above (Schemes 1-4).

The presence of aldehydes, among other reactants, leads to an increase in the molecular weight of gelatin, likely due to formation of interstrand bridges across its polypeptide backbone.<sup>9</sup>





hexamethylenetetramine



### Scheme 5

This cross-linking reaction has been utilized to prepare gelatin capsules which are resistant to gastric juice.<sup>21-23</sup> Formaldehyde, the main cross-linking agent related to the loss of solubility of gelatin capsules, is believed to react with the  $\epsilon$ -amino function of lysine<sup>1</sup> and the guanidino function of arginine residues present in gelatin.<sup>4-6</sup>

In addition to formaldehyde, other aldehydes may present problems to gelatin-encapsulated drug formulations. For example, it has recently been shown that gelatin capsules packaged in bottles containing rayon coilers exhibit decreased in vitro dissolution rates after 2 months at 40 °C and relative humidities of 18% to 75%.<sup>23</sup> The rayon process involved in coiler production uses cellulose, which contains low levels of hemicellulose (i.e. pentosans), as a starting material. The chemical process for rayon production involves an acid treatment. Under these conditions, hemicellulose produces pentose sugars which, in turn, can form furfural. Subsequently, the aldehydic function of furfural has been shown to react rapidly with gelatin to form a cross-linked insoluble product.<sup>23</sup>

Plasticizers and preservatives, fats and polyethylenated compounds such as polyethylene glycols, ethers of polyethylene glycol and aliphatic alcohols or phenols, polyoxyethylenated glycerides, and nonionic surfactants (polysorbates, esters of unsaturated fatty acids) are frequently used in soft gelatin capsules. These compounds can undergo autoxidation to form aldehydes of higher molecular weights.<sup>9,24</sup> The latter can react with gelatin to form cross-linked products resulting in lower in vitro dissolution rates.<sup>24</sup> This type of cross-linking is usually absent in hard gelatin capsules since they do not contain the plasticizers or preservatives inherent to soft gelatin capsules.

The influence of ultraviolet light on gelatin capsule cross-linking has been investigated using gemfibrozil, hydrochlorothiazide, and diphenhydramine hydrochloride, along with the various dyes present in the capsules.<sup>16</sup> It was found that intense UV or visible irradiation promoted changes in the gelatin which resulted in lower in vitro dissolution rates. This effect was especially pronounced when the irradiation was combined with conditions of high humidity and gelatin capsules containing FD&C Red No. 3 or 40.<sup>16,25</sup> Many FD&C dyes have been known to interact with gelatin via hydrophobic and hydrogen bonding.<sup>1,26</sup> In addition, Kellaway et al. have demonstrated a correlation between the increase in gelatin molecular weight and the quantity of bound dye.<sup>27</sup>

In summary, the presence of aldehydes, dyes, high humidity, and prolonged exposure to light may play a separate or synergistic role in increasing the *in vitro* dissolution times of drug substances from gelatin capsules by altering the disintegration of gelatin capsules. In such cases the capsules are often referred to as being "stressed".

## Reversibility of Cross-Linking

**1. Nonenzymatic**—The reversibility of the aminal reaction (Scheme 3, step 4), as well as that of the imine functionality, shows a definite pH dependence (Scheme 3, steps 2 and 3). In general, the aminal decomposition (Scheme 3, step 4) is reversible under basic conditions<sup>13,14</sup> while steps 2 and 3 (imine to carbinolamine) are reversible in acidic media. Carbinolamine decomposition (step 1) occurs under basic conditions.<sup>13,14</sup>

**2. Enzymatic**—The impeding barrier that is exerted upon drug molecules by a highly cross-linked gelatin capsule wall can be alleviated by the presence of pepsin and/or pancreatin.<sup>25,28,29</sup> Gastric juice, at pH 1.2, consists mainly of the enzyme pepsin, an acid-dependent endopeptidase which cleaves peptides proximal to hydrophobic and aromatic amino acids (Figure 1).<sup>30</sup>

Likewise, pancreatin, which contains the protease enzyme trypsin, an endopeptidase which operates at neutral pH and preferentially cleaves the carboxyl side of lysine and arginine residues,<sup>30</sup> hydrolyzes specific peptide linkages of gelatin, thus liberating the drug which it encapsulates. Figure 1 illustrates the dual effect of pepsin and pancreatin on scission of certain peptide bonds within the gelatin molecule.

## Comparison of the *in Vitro* Dissolution Rate of Drugs, Formulated in Gelatin Capsules, with Their *in Vivo* Bioavailability

The investigation of the relationship between dissolution rates of drugs and their bioavailabilities in humans is necessary to establish meaningful *in vitro* dissolution tests.

In order to obtain an *in vitro*-*in vivo* correlation for any product, it is necessary to have products which differ in their *in vivo* performance as well as in their *in vitro* behavior. The *in vivo* performance of the product is invariable and cannot be altered. On the other hand, the *in vitro* parameters are variable and are dependent on the method, stirring rate, dissolution medium, and other variables and can be adjusted to mimic the *in vivo* performance of the product. The *in vivo* parameters such as AUC (area under the plasma concentration curve),  $t_{\max}$  (time to reach maximum concentration),  $C_{\max}$  (maximum concentration), or  $A_e$  (cumulative amount of drug excreted unchanged in urine) of the products are obtained from the biostudies and are commonly utilized in the correlation. The *in vitro* dissolution rates of the products are generally determined using the basket or paddle method (U.S. Pharmacopoeia apparatus 1 or 2) in a suitable dissolution medium at the appropriate degree of agitation, and the percent dissolved at a specified time or the time needed to dissolve a certain percentage is utilized in the correlation. The key elements are the proper choice of the medium and degree of agitation. In developing an *in vitro* test, it is important not to make the method more complicated than is necessary and also not to develop a method that is overly discriminatory. In order to obtain a correlation, at the minimum, three products differing in *in vivo* and *in vitro* dissolution rate are required. With less than three products, only a rank-order relationship can be obtained. If there is no difference in *in vivo* parameters, only association can be obtained.

In earlier studies, Shah et al.<sup>31,32</sup> conducted two studies (single and multiple dose) using slow-dissolving and fast-dissolving phenytoin sodium capsule preparations. Each of these products was tested utilizing healthy volunteers and epileptic patients. A good correlation was obtained with the *in vitro* dissolution rates and *in vivo* parameters for each of the two phenytoin sodium capsules.<sup>32</sup> On the basis of these studies, *in vitro* experimental specifications were recommended for fast and slow-dissolving phenytoin sodium capsule products which were shown not to be interchangeable because of significant differences in their dissolution behavior and *in vivo* performance.<sup>32</sup>

Utilizing a dissolution simulator, Yau and Meyer<sup>33</sup> obtained *in vivo*-*in vitro* correlations for 11 phenytoin formulations. These workers found the dissolution of the majority of the phenytoin capsules to be quite rapid, with all but three of the 11 products being at least 85% dissolved within 10 min. Among these eight capsule products, a good *in vitro* and *in vivo* correlation was found. The product with the slowest dissolution profile exhibited the poorest *in vivo* bioavailability.<sup>33</sup>

In another study involving hard gelatin capsules, an *in vivo*-*in vitro* correlation was obtained using seven tetracycline hydrochloride products.<sup>34</sup>

A correlation between the dissolution rate and bioavailability for five indomethacin capsules was investigated in human subjects.<sup>35</sup> A good correlation between the *in vivo* parameters, such as AUC,  $t_{max}$ ,  $C_{max}$ , and *in vitro* dissolution rates were obtained using the paddle method at slow stirring rates. This emphasizes that the choice of conditions of *in vitro* test methods is one of the important factors in obtaining good *in vitro*-*in vivo* correlations.

These are some of the examples of gelatin-encapsulated products where a good *in vivo*-*in vitro* correlation for immediate release products was observed. It is important to emphasize that it is not easy to obtain the correlation. It requires products with varying *in vivo* performance and also *in vitro* methodology that can differentiate between the products. There may be cases where no correlation has been observed, *i.e.*, where products differ in *in vivo* but not in *in vitro* and vice versa.

### The *In Vitro* and *In Vivo* Dissolution of a Drug from Stressed Gelatin Capsules

The adverse effect of prolonged storage on *in vitro* disintegration and on subsequent drug release from gelatin capsules has long been known.<sup>36</sup> Changes in *in vitro* dissolution due to exposure to high humidity have been observed in capsules containing chloramphenicol,<sup>37,38</sup> tetracycline,<sup>38</sup> nitrofurantoin,<sup>39</sup> and either water-insoluble or relatively water-soluble agents.<sup>16</sup> The principal concern is to determine the effect of prolonged storage conditions on the bioavailability and/or the clinical efficacy of a drug from gelatin capsules or gelatin-coated tablets. More specifically, an effort has been made in recent years to develop *in vitro* dissolution tests which provide better indication of stressed gelatin capsule performance *in vivo*.

It has been shown recently that hard gelatin capsules tested in a dissolution medium containing enzymes such as pepsin and pancreatin would negate the effects of adverse storage conditions (such as high humidity and temperatures, and also severe light conditions) on the *in vitro* dissolution performance of capsules.<sup>25</sup> Murthy *et al.*<sup>25</sup> have demonstrated that the inclusion of gastrointestinal enzymes may better simulate the physiologic conditions that an orally administered capsule would encounter during its transit through the gastrointestinal tract. More recently, Dahl *et al.*<sup>28</sup> have shown that there was no change in the *in vitro* dissolution (deionized water as a medium) performance of gelatin-coated acetaminophen (*p*-acetaminophenol) tablets which were stored up to 7 months at room temperature. When these gelatin-coated tablets, however, were stored in the presence of high humidity for 3.5 and 7 months, a significant reduction in both the amount of drug released and standard deviations at each time point were observed.<sup>28</sup> In contrast to the above observations, when the gelatin-coated acetaminophen tablets stored in a humidity chamber for 7 months were tested in a 1% aqueous pancreatin solution, they exhibited the same dissolution profile as tablets stored for seven months at room temperature and also freshly prepared<sup>28</sup> gelatin-coated tablets.

In a series of studies, Mohamad *et al.*<sup>11,12</sup> have demonstrated that the partial insolubilization of the gelatin shell, observed *in vitro* after storage of hard gelatin capsules for 48 months, did

not occur *in vivo*. More specifically, these workers showed that while the rate of the *in vitro* dissolution (in media containing no enzymes) of tetracycline hydrochloride from hard gelatin capsules stored for 48 months at ambient temperature was decreased, no differences in the bioavailability of the antibiotic were observed *in vivo*.<sup>11,12</sup> Similar results were observed by these investigators with hard gelatin capsules containing ampicillin trihydrate.<sup>40</sup> The time required for 50% of ampicillin trihydrate to dissolve from hard gelatin capsules stored for 42 months at room temperature was significantly increased when compared to dissolution times of the antibiotic from freshly prepared capsules. The two batches, however, exhibited comparable bioavailabilities and were found to be bioequivalent when tested in a clinical study involving six human subjects.<sup>40</sup>

In an elegant study, Dey *et al.*<sup>29</sup> demonstrated that stressed (high humidity and temperature, 75% relative humidity, 40 °C) hard gelatin capsules containing 200 and 300 mg of etodolac (a nonsteroidal anti-inflammatory/analgesic drug) which failed *in vitro* dissolution tests in phosphate buffer (pH 7.5) met dissolution specifications (not less than 85% drug release in 30 min) when tested in phosphate buffer (pH 7.5) containing 1% w/v pancreatin. Furthermore, the rate and extent of absorption of the drug from the stressed 200 and 300 mg etodolac capsules in dogs were equivalent to capsules stored at room temperature that passed *in vitro* dissolution tests. Interestingly, the bioavailability of etodolac from 300-mg stressed capsules that failed the dissolution specifications was shown to be equivalent to that of control capsules (fresh, packaged) in 24 adult male volunteers.<sup>29</sup>

The aforementioned studies performed on stressed hard gelatin capsules were overly discriminatory and do not reflect the *in vitro* performance of the product. On the other hand, dissolution of stressed capsules in the presence of enzymes is fairly rapid, is nearly the same as in prestress conditions, and is a better reflection of the *in vivo* behavior of the product.

### Test Methods

In general, the characteristics of a dosage form are determined by a number of factors such as the nature of the drug, its excipients, packaging form,<sup>23</sup> and storage conditions to which it is subjected.<sup>41</sup> Each aspect must be weighed carefully when investigating a dissolution problem with the dosage form.

As mentioned earlier, shell-disintegration problems can arise due to interactions between the gelatin shell and other chemical components within the capsule shell. These interactions should be separated from drug-capsule wall interactions. It is possible, for example, to carry out diagnostic tests for gelatin/fill interactions by stress-storing the final product and separately testing the gelatin shell from the fill. Additionally, hard gelatin capsules can be emptied after subjecting them to stressed conditions and then refilled with fresh drug blend. The subsequent dissolution tests could reveal the effect of any possible capsule-fill interactions on the dissolution of the second fill. The classic example of capsule-excipient interaction is from formaldehyde contamination of excipients, for which sensitive detection methods are available.<sup>24</sup>

In the case of all types of oral dosage forms there exist concerns regarding the ability of *in vitro* tests to predict *in vivo* performance. From the above discussion, it appears that for hard gelatin encapsulated dosage forms, the current *in vitro* dissolution tests on stressed-stored products tend to underestimate the *in vivo* dissolution rate of a drug. Hence, critical planning is needed when choosing the *in vitro* dissolution and storage stability testing methods. For gelatin-containing dosage forms, the absence of digestive enzymes from the *in vitro* test medium is an important shortcoming,<sup>25,28,29</sup> giving artificial negative results concerning the role of the gelatin envelope. In fact, serious doubts have been raised as to whether a dissolution

test conducted in an enzyme-free medium can provide meaningful results<sup>41</sup> with regard to the in vivo performance of gelatin-encapsulated products. Additionally, simulation of long-term storage tests utilizing high temperature/humidity conditions, although necessary, can produce misleading results if they are not well validated. These conditions could trigger reactions within the gelatin shell, or between the gelatin shell and its contents, which would not occur at lower temperature. In this connection it should be noted that the initial water content of the gelatin shell or the gelatin formulation must be accurately measured. Loss of moisture content from the gelatin dosage form may have serious repercussions on the dissolution profile of the drug it contains. Recently, a sensitive technique which is rapid and noninvasive to the capsules utilizing near-infrared methodology has been successfully applied in these laboratories for the determination of moisture content in hard gelatin capsules.<sup>42</sup>

## Conclusions

(1) The advantages and limitations of gelatin-containing dosage forms are well-described in the literature. Cross-linking phenomena, occurring in stressed hard gelatin capsules and gelatin-coated tablets, could cause considerable changes in the in vitro dissolution profiles of drugs. However, in a few limited cases identified in the literature, the bioavailability of the drug from the stressed capsules is not significantly altered when compared to that obtained from freshly packed capsules.

(2) It is important to consider the interactions that occur with the presence of certain chemical entities which may contribute to the occurrence of gelatin cross-linking in the gelatin shell of a dosage form. Thus, careful attention should be paid to the purity and chemical reactivity of all of the excipients that are to be encapsulated in a gelatin shell. This is particularly true with soft gelatin capsules, which are considerably more prone to cross-linking phenomena than hard gelatin capsules since their shells usually contain added materials such as plasticizers and preservatives.

(3) It is suggested that in vitro dissolution tests of hard gelatin-containing dosage forms be conducted in two stages, firstly in a dissolution medium without enzymes and secondly in dissolution media containing enzymes (pepsin at pH 1.2 or pancreatin at pH 7.2, representing gastric and intestinal media, respectively<sup>43</sup>) prior to in vivo evaluation. It is suggested that such in vitro tests may constitute a better indication of the in vivo behavior of gelatin-encapsulating formulations.

(4) Testing for contamination with formaldehyde as well as low molecular weight aldehydes should be a standard part of excipient evaluation procedures.

## References and Notes

- Jones, B. E. In *Hard Capsules—Development and Technology*; Ridgway, K., Ed.; The Pharmaceutical: London, U.K., 1987; pp 39–48.
- Merck Index*, 11th ed.; Budavari, S., Ed.; Merck: Rahway, N.J., 1989; p 685.
- Bubnis, W. A.; Ofner, C. M. *Anal. Biochem.* **1992**, *207*, 129–133.
- Albert, K.; Peters, B.; Bayer, E.; Treiber, U.; Zwilling, M. *Z. Naturforsch.* **1986**, *41b*, 351–358.
- Albert, K.; Bayer, E. *Z. Naturforsch.* **1991**, *46b*, 385–389.
- Taylor, S. K.; Davidson, F.; Overall, D. W. *Photogr. Sci. Eng.* **1978**, *22*, 134–138.
- Marks, E. M.; Tourtellotte, D.; Andux, A. *Food Technol.* **1968**, *22*, 1433–1436.
- Franzblau, C. In *Comprehensive Biochemistry*; Florin, M.; Stotz, E. H., Eds.; Elsevier: New York, 1971; Vol. 26c, pp 659–712.
- Doelker, E.; Vial-Bernasconi, A. C. *S.T.P. Pharma.* **1988**, *4*, 298–306.
- Mohamad, H.; Renoux, R.; Aiache, S.; Aiache, J.-M. *S.T.P. Pharma.* **1986**, *2*, 531–535.
- Mohamad, H.; Renoux, R.; Aiache, S.; Aiache, J.-M.; Kantelip, J.-P. *S.T.P. Pharma.* **1986**, *2*, 630–635.
- Mohamad, H.; Aiache, J.-M.; Renoux, R.; Mougin, P.; Kantelip, J.-P. *S.T.P. Pharma.* **1987**, *3*, 407–411.
- Cordes, E. H.; Jencks, W. P. *J. Am. Chem. Soc.* **1962**, *84*, 832–837.
- Koehler, K.; Sandstrom, W.; Cordes, E. H. *J. Am. Chem. Soc.* **1964**, *86*, 2413–2419.
- Hodge, J. E. *Adv. Carbohydr. Chem.* **1955**, *10*, 169.
- Murthy, K. S.; Enders, N. A.; Fawzi, M. B. *Pharm. Technol.* **1989**, *13*, 72–86.
- Pankhurst, K. G. A. *Nature* **1947**, *159*, 538.
- Bradbury, E.; Martin, C. *Proc. R. Soc. A.* **1952**, *214*, 183–192.
- Finch, C. A.; Jobling, A. In *The Science and Technology of Gelatin*; Ward, A. G.; Courts, A., Eds.; Academic: New York, 1977; pp 249–294.
- Martin, A. In *Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry*, 9th ed.; Delgado, J. N.; Remers, W. A., Eds.; J. B. Lippincott: New York, 1991; p 157.
- Palermo, B. T.; McMillion, S. C. Method of treating gelatin capsules and product resulting therefrom, U.S. Patent 2 578 943, 1951.
- Swinyard, E. A.; Lowenthal, W. In *Pharmaceutical Necessities in Remington's Pharmaceutical Sciences*, 18th ed.; Gennaro, A. R., Ed.; Mack: Eaton, PA; 1990, p 1306.
- Schwier, J. R.; Cooke, G. G.; Hartauer, K. J.; Yu, L. *Pharm. Tech.* **1993**, *17*, 78–79.
- Chafetz, L.; Hong, W.; Tsilifonis, D. C.; Taylor, A. K.; Philip, J. J. *Pharm. Sci.* **1984**, *73*, 1186–1187.
- Murthy, K. S.; Reisch, R. G., Jr.; Fawzi, M. B. *Pharm. Technol.* **1989**, *13*, 53–58.
- Cooper, J. W.; Ansel, H. C.; Cadwallader, D. E. *J. Pharm. Sci.* **1973**, *62*, 1156–1164.
- Kellaway, I. W.; Marriott, C.; Robinson, J. A. *J. Can. J. Pharm. Sci.* **1978**, *13*, 87–90.
- Dahl, T. C.; Sue, I.-L. T.; Yum, A. *Pharm. Res.* **1991**, *8*, 412–414.
- Dey, M.; Enever, R.; Kraml, M.; Prue, D. G.; Smith, D.; Weierstall, R. *Pharm. Res.* **1993**, *10*, 1295–1300.
- Walsh, C. *Enzymatic Reaction Mechanisms*; W. H. Freeman: San Francisco, 1979; pp 53–55, 98–104.
- Shah, V. P.; Prasad, V. K.; Alston, T.; Cabana, B. E.; Gural, R. P.; Meyer, M. C. *J. Pharm. Sci.* **1983**, *72*, 306–308.
- Shah, V. P.; Prasad, V. K.; Freeman, C.; Skelly, J. P.; Cabana, B. E. *J. Pharm. Sci.* **1983**, *72*, 309–310.
- Yau, M. K. T.; Meyer, M. C. *J. Pharm. Sci.* **1983**, *72*, 681–686.
- Shah, V. P.; Hunt, J. P.; Fairweather, W. R.; Prasad, V. K.; Knapp, G. *Biopharm. Drug Dispos.* **1986**, *7*, 27–33.
- Aoyagi, N.; Ogata, H.; Kaniwa, N.; Ejima, E. *Int. J. Clin. Pharmacol. Ther. Toxicol.* **1985**, *23*, 529–534.
- Johnson, B. F.; Mcauley, P. V.; Smith, P. M.; French, J. A. G. *J. Pharm. Pharmacol.* **1977**, *29*, 576–578.
- Khalil, S. A. H.; Ali, L. M. M.; Abdel Khalek, M. M. *Pharmazie* **1974**, *29*, 36–37.
- York, P. *Pharmazie* **1977**, *32*, 101–104.
- Gouda, H. W.; Moustafa, M. A.; Al-Shora, H. I. *Int. J. Pharm.* **1984**, *18*, 213–215.
- Mohamad, H.; Renoux, R.; Aiache, S.; Aiache, J.-M.; Sirot, J.; Kantelip, J.-P. *S.T.P. Pharma.* **1986**, *2*, 912–917.
- Murthy, K. S.; Ghebre-Sellassie, I. *J. Pharm. Sci.* **1993**, *82*, 113–126.
- Buice, R., Jr.; Gold, T.; Lodder, R.; Digenis, G. Submitted.
- U.S. Pharmacopeia*, 22 rev.; U.S. Pharmacopeial Convention: Rockville, MD, 1990; pp 1788–1789.